News · 26 weeks59-57%
2026-03-012026-08-23
Mix1990d
- Other7(37%)
- SEC Filings7(37%)
- Insider2(11%)
- Earnings2(11%)
- Analyst1(5%)
Latest news
25 items- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Reports Second Quarter 2026 Financial Results and Operational HighlightsRecord second quarter 2026 revenue increased 35% to $17.1 million, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20% Remaining performance obligations grew 30% year-over-year to $80.4 million Shipped a record total 125 Deep TMS systems in Q2 2026, a 42% increase year-over-year Raises FY 2026 revenue and EBITDA guidance BURLINGTON, Mass. and JERUSALEM, Aug. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported its second quarter 2026 financial results and p
- PRBrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will report its second quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. US Conference Call Dial-In & Webcast Information In English: Date:Wednesday, August 12, 2026Time:8:30 AM Eastern TimeUnited States:1-877-269-7751In
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.SCHEDULE 13G/A - Brainsway Ltd. (0001505065) (Subject)
- ANALYSTBTIG Research initiated coverage on Brainsway with a new price targetBTIG Research initiated coverage of Brainsway with a rating of Buy and set a new price target of $18.00
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Announces Strategic Investment in Radial Health, Inc.BURLINGTON, Mass. and JERUSALEM, July 20, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced a $3 million minority equity investment in Radial Health, Inc. ("Radial"), a management services organization supporting a leading network of Brain Medicine clinics across the country. The investment was made as part of Radial's previously-announced Series A financing, and BrainsWay joins other leading investors in Radial, including General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van La
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Announces Minority-Stake Investment in Sound Minds BehavioralBURLINGTON, Mass. and JERUSALEM, July 16, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its participation in a strategic equity financing round with Sound Minds Behavioral, a leading growth-oriented outpatient behavioral health platform with multiple locations throughout Connecticut, Pennsylvania, New Jersey and New York ("Sound Minds Behavioral" or "Sound Minds"). Under the terms of the agreement, BrainsWay will invest $500,000 for a minority position in Sound Minds in the form of a preferred, annually compounding security. "We
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive DisorderNearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD ~83.5% of patients with comorbid PTSD and MDD experienced a response (reduction in PTSD symptoms of ≥50%) following Deep TMS, with a mean reduction of 52% Results presented at a recent leading industry conference BURLINGTON, Mass. and JERUSALEM, June 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced the presentation of positive new real-world data demonst
- INSIDERChief Technology Officer Moiseyev Gilad converted options into 7,500 units of Ordinary Shares, covered exercise/tax liability with 1,902 units of Ordinary Shares and sold 5,000 units of Ordinary Shares, increasing direct ownership by 1% to 53,098 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered LivesBURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OC
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual MeetingBURLINGTON, Mass. and JERUSALEM, June 09, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the presentation of new prospective 12-month durability data demonstrating sustained clinical benefits following accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Major Depressive Disorder (MDD). The findings were recently presented in a poster by Colleen Hanlon, PhD, Vice President of Medical Affairs for BrainsWay, at the 14th Annual Clinical TMS Society (CTMSS) Meeting which was held on June 4-6, 2026. The data represented outcomes from the first multisite, randomized, controll
- INSIDERChief Scientist Roth Yiftach sold 7,000 units of Ordinary Shares, decreasing direct ownership by 0.65% to 1,072,305 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.SCHEDULE 13G/A - Brainsway Ltd. (0001505065) (Subject)
- INSIDERDirector Mitrany Rayten Michal Ety sold 17,980 units of Ordinary Shares, decreasing direct ownership by 59% to 12,500 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERDirector Mitrany Rayten Michal Ety converted options into 27,500 units of Ordinary Shares and covered exercise/tax liability with 9,520 units of Ordinary Shares, increasing direct ownership by 144% to 30,480 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Announces Minority-Stake Investment in Hopemark HealthBURLINGTON, Mass. and JERUSALEM, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with APS Innovations LLC, the parent company of Advanced Psychiatric Management LLC, a management services organization servicing multiple mental health clinics in the greater Chicago area (collectively, "Hopemark Health" or "Hopemark"). Under the terms of the agreement, BrainsWay will invest $1.5 million initially, with potential for an additional $1.5 million via milestone-based
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.SCHEDULE 13G/A - Brainsway Ltd. (0001505065) (Subject)
BWAY FAQ
7 questionsWhat does BrainsWay Ltd. do?
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying...Where does BWAY stock trade?
BrainsWay Ltd. (BWAY) is listed on NASDAQ.What sector and industry is BWAY in?
BrainsWay Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.When did BrainsWay Ltd. go public?
BrainsWay Ltd. (BWAY) completed its IPO in 2019.What are analysts saying about BWAY?
BrainsWay Ltd. has had 6 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1800.00 price target on 2026-07-20. Recent price targets range from $1400.00 to $1800.00.What companies are similar to BWAY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare BWAY side-by-side with any of them on Quantisnow.How can I track BWAY on Quantisnow?
Quantisnow aggregates BrainsWay Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BWAY to receive live email and push alerts on every new disclosure.